Lupus Trial, Recruiting NCT06796569 Sponsor: Sohag University Condition: Lupus
Back to Lupus

Lupus Trial, Recruiting

NCT06796569
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 16 years of age
  • People who have been diagnosed with Systemic Lupus Erythematosus (SLE) — a type of autoimmune disease — where the diagnosis meets the official guidelines set by two major international rheumatology organisations (ACR and EULAR)
  • People who have Lupus Nephritis (a form of kidney inflammation related to lupus), where the diagnosis has been confirmed through a kidney biopsy and laboratory examination of the tissue, classified according to recognised medical systems

Who may not be able to join:

  • People who have other autoimmune or rheumatological diseases (conditions where the immune system attacks the body)
  • People who have lymphoproliferative disorders (diseases affecting the lymph system, such as certain types of lymphoma)
  • People who have been diagnosed with cancer
  • People who have liver disease
  • People who have end-stage kidney disease (very advanced kidney failure)
  • People who have diabetic nephropathy (kidney disease caused by diabetes)
  • People who have an active infection at the time of the trial
  • People who have recently received a blood transfusion
  • People who have low levels of vitamin B12, folate, or iron

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 02 +01099082079

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
2 December 2024
Est. completion
1 December 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

association of systemic immune-inflammation index (SII) disease activity in systemic lupus erythematosus; association of systemic immune-inflammation index (SII) and lupus nephritis in patients with systemic lupus erythematosus

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov